Why the study?
Does mandatory contrast-enhanced venography accurately reflect patient-important outcomes in trials of DVT prophylaxis?
Does mandatory contrast-enhanced venography accurately reflect patient-important outcomes in trials of DVT prophylaxis?
The use of mandatory venography as an efficacy endpoint in DVT prophylaxis trials is limited because it primarily detects clinically unimportant asymptomatic thrombi.
Venography endpoints in DVT prophylaxis trials detect mostly asymptomatic thrombi; leaves open correlation with patient-important outcomes.
The introduction of venography into patient care was a major advance because it was the first accurate method for the diagnosis of DVT. Compression ultrasound has since become the preferred test for patients with suspected DVT because, unlike venography, it is simple, non-invasive and widely available. Venography has facilitated the development and approval of new anticoagulants and remains widely used as an efficacy outcome in trials of venous thromboembolism prevention. Most thrombi detected by screening venography are, however, small and unimportant for patients. In order to calculate the trade-off between an asymptomatic thrombus and a bleed we require an estimate of the number of asymptomatic thrombi that must be prevented to avoid a patient-important thrombus. A credible estimate of this ratio is not available. Therefore when used as a measure of efficacy in trials of thromboprophylaxis, venography has limitations for comparing the relative effects of alternative antithrombotic agents on outcomes important to patients.
No takes yet. Share an insight, caveat, or question.
Hirsh et al. (2013) conducted an editorial in Deep-vein thrombosis (DVT). Mandatory contrast-enhanced venography was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: